t(9;22)(q34.1;q11.2)BCR::ABL1 (BCR-ABL+): This category comprises a subset of de novo AML developed in patients without a history of chronic myeloid leukemia (CML) and lacking recurrent genetic aberrations affecting the CEBPA or NPM1 gene, or cytogenetic alterations such as inv(16) or inv(3). This evidence concerns the gene NPM1 and chronic myelogenous leukemia, BCR-ABL1 positive.